Charles Schwab Investment Management Inc Cyteir Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$1.74 - $2.6 $27,791 - $41,527	15,972 New	15,972 $41,000
Q2 2022 Aug 15, 2022	SELL	$1.62 - $4.4 $67,777 - $184,087	-41,838 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$3.39 - $10.51 $64,786 - $200,856	19,111 Added 84.09%	41,838 $158,000
Q4 2021 Feb 11, 2022	BUY	$9.83 - $19.21 $21,213 - $41,455	2,158 Added 10.49%	22,727 $259,000
Q3 2021 Nov 16, 2021	BUY	$14.57 - $21.86 $299,690 - $449,638	20,569 New	20,569 $361,000

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.